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cardiovascular (CV) risk of NSAIDs, partially triggered by the withdrawal of rofe-
coxib. Small increases in BP associated with NSAID use contribute to the CV toxicity 
of NSAIDs. OA patients often have an elevated risk for CV events due to characteris-
tics common to this population; advanced age, obesity, and co-morbidities such as 
diabetes, hypertension and other CV risks. In order to quantify the potential health 
economic beneﬁts of improvement in the BP proﬁle of NSAIDs, an individual state 
transition model (one year cycles, 5-year treatment duration, life-time model horizon, 
health care perspective) encompassing eight CV events (congestive heart failure, stroke, 
transient ischemic attack, myocardial infarction, stable angina, unstable angina, stroke 
death and MI death) caused or exacerbated by increases in BP was constructed. The 
model was populated with UK data. The model was used to estimate potential cost 
savings and QALY beneﬁts from avoided cardiovascular events associated with four 
levels of relative risk reductions (RRRs) with a hypothetical NSAID (5%, 10%, 15%. 
20% and 25%) compared to naproxen—widely regarded the NSAID with the most 
benign CV proﬁle currently on the market—at three levels of absolute 10-year primary 
CV risk (20%, 30% and 40%). RESULTS: As expected the cost savings and QALY 
beneﬁts associated with avoided cardiovascular events increased with the level of RRR 
and 10-year absolute CV risk. Potential cost savings ranged from GBP 181 to GBP 
1,591, whereas the QALY beneﬁts ranged from 0.05 to 0.44. CONCLUSIONS: An 
NSAID with an improved BP proﬁle has the potential to provide signiﬁcant health 
economic beneﬁts, especially in patients with elevated CV risk.
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OBJECTIVES: Analyse the costs and outcome of treating osteoporosis in Germany 
with either a combination of Alfacalcidol, Alendronate and 500 mg calcium (regime 
1) or plain vitamin D, Alendronate and 1000 mg calcium (regime 2). METHODS: A 
Markov model was created and a time horizon of 2, 5 and 10 years were evaluated. 
Patients could be in the state of well, fracture, post fracture and dead. Data were 
extracted from published clinical trials and register based studies. RESULTS: Treat-
ment regime 1 are associated with lower costs compared to treatment regime 2. The 
drug costs in regime 1 are above the drug costs in regime 2 (a2191/patient vs. a1392/
patient). However, when taking into account that the risk of fractures is signiﬁcantly 
lower for patients treated in regime 1, treatment regime 1 becomes cost saving over 
a 2 year time horizon compared to regime 2 (a3142/patient vs. a4782/patient). Regime 
1 is also the most effective alternative measured in QALYs. On a 2 year time horizon 
the patients in treatment regime 1 gain 1.4956 QALYs. In comparison, patients from 
regime 2 gains 1.4242 QALYs, i.e. regime 1 is dominating regime 2. In 2003, around 
7.8 million Germans, or around 25% of the population above the age of 50, were 
estimated to suffer from osteoporosis. Taking into account the savings per patient 
when treating with regime 1, there is a signiﬁcant saving potential for Germany. 
CONCLUSIONS: Lowest total cost of treatment is obtained when osteoporosis 
patients are treated with Alfacalcidol in combination with Alendronate and 500 mg 
calcium. Even though the initial cost of plain vitamin D, Alendronate 1000 mg 
calcium is lower, the Alfacalcidol regime is more cost effective, due to a signiﬁcantly 
lower risk of fractures. Furthermore, the Alfacalcidol regime is more effective mea-
sured in QALYs.
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OBJECTIVES: To evaluate the cost-effectiveness of leﬂunomide used before tumor 
necrosis factor (TNF) inhibitors compared with leﬂunomide after TNF inhibitors in 
the sequence treatment of rheumatoid arthritis (RA) following the failure of 2 disease-
modifying antirheumatic drugs (DMARDs) in Polish setting. METHODS: A cost-
utility approach was adopted, evaluating total direct costs incurred by the National 
Health Fund (NHF) and quality-adjusted life years (QALY). A micro-simulation 
Markov model was used to estimate utilities and costs. Simulation was executed in 6 
months cycles and terminated at the time of the patient’s death. Transition probabili-
ties between health states were calculated based on a systematic review of RCTs and 
supplemented with published literature if necessary. Health states utilities were taken 
from published literature. Probabilistic sensitivity analysis was performed. The starting 
time-point of the model was the failure of two previous DMARDs. Six treatment 
options were compared. Upon treatment failure it was assumed patients would follow 
an identical lifetime treatment strategy consisting of: LIM—leﬂunomide, inﬂiximab, 
methotrexat, LEM—leﬂunomide, etanercept, methotrexat, LAM—leﬂunomide, adali-
mumab, methotrexat, ILM—inﬂiximab, leﬂunomide, methotrexat, ELM—etanercept, 
leﬂunomide, methotrexat, ALM—adalimumab, leﬂunomide, methotrexat. RESULTS: 
Sequences with leﬂunomide at the beginning of the RA treatment (LIM, LAM, LEM) 
were dominant over schedules with leﬂunomide used after TNF inhibitors (ILM, ELM, 
ALM). Detailed results: LIM vs. ILM (cost difference—7,788 PLN, QALY difference 
—0.002); LEM vs. ELM (cost difference—18,871 PLN, QALY difference—0.004); 
LAM vs. ALM (cost difference—11,377 PLN, QALY difference—0.016). CONCLU-
SIONS: The model predicted that leﬂunomide should be used before TNF inhibitors. 
LEM, LAM, LIM sequences for RA patients who have failed DMARDs therapy are 
less costly and more effective than sequences with leﬂunomid administrated after TNF 
inhibitors (ILM, ELM, ALM).
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INTRODUCTION: Osteoporosis is a common illness frequently leading to serious 
adverse outcomes for patients. Hip, wrist and vertebral fractures have considerable 
impact on both costs to health care system and lives of those who suffer from those 
events. Each year in the US, an estimated 1.5 million fractures occur due to osteopo-
rosis [Riggs and Melton, 1995]. Estimated incremental cost of osteoporosis related 
events in subsequent years after fracture is US$4.007 [Rousculp, 2007]. Bisphospho-
nates are widely used and are considered an effective intervention for risk reduction 
of postmenopausal fractures. OBJECTIVES: The present study was conducted to 
compare the cost of bisphosphonates used for risk reduction of post-menopause ver-
tebral and non-vertebral fractures under public payer (SUS) perspective in Brazil. 
METHODS: The most important bisphosphonates in the public market are ibandro-
nate (oral and IV), zolendronate, alendronate and risendronate. There are no head-
to-head clinical trials comparing all compounds. Studies of ibandronate IV [Eisman, 
2008] and zolendronate IV [McClung, 2007] demonstrated their non-inferiority 
against oral bisphosphonates. Therefore, a cost-minimization approach was taken. 
Drug acquisition costs took into account was the maximum sales price to government. 
Administration costs were obtained from SUS reimbursement database (SIA/SUS, 
2006). Since the time horizon of this analysis is one-year, no discount rate was utilized. 
Costs are presented in Brazilian Reais (US$1.00^R$2.00 in May 2009). RESULTS: 
Total cost per patient was R$814.12 for IV ibandronate, R$915.59 for alendronate, 
R$1054.32 for oral ibandronate, R$1054.97 for zolendronate and R$1278.81 for 
risendronate. Administration costs represented about 9% and 2% of total cost of 
ibandronate (administrated four times a year) and zolendronate (administrated once 
a year), respectively. CONCLUSIONS: Findings suggest IV ibandronate is a cost-
saving therapy with potential of reducing total treatment cost per patient from 11% 
to 36%, when compared to alendronate and risedronate respectively, under public 
payer perspective.
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BACKGROUND: Osteoporosis is a common illness frequently leading to serious 
adverse outcomes for patients. Hip, wrist and vertebral fractures have considerable 
impact on both costs to health care system and lives of those who suffer from those 
events. Each year in the US, an estimated 1.5 million fractures occur due to osteopo-
rosis [Riggs and Melton, 1995]. Estimated incremental cost of osteoporosis related 
events in subsequent years after fracture is US$4007 [Rousculp, 2007]. Bisphospho-
nates are widely used and are considered an effective intervention for risk reduction 
of postmenopausal fractures. OBJECTIVES: The present study was conducted to 
compare the cost of IV bisphosphonates used for risk reduction of post-menopause 
vertebral and non-vertebral fractures under the private payer perspective in Brazil. 
METHODS: According to local legislation, private payers are not obliged to cover 
oral drugs, therefore, oral forms of biphosphonates were not considered in this study. 
The most important IV bisphosphonates in the private market are ibandronate and 
zolendronate. There are no head-to-head clinical trials comparing both compounds. 
Both studies of ibandronate [Eisman, 2008] and zolendronate [McClung, 2007] dem-
onstrated their non-inferiority against oral bisphosphonates. Therefore, a cost-
 minimization approach was taken. Drug prices were obtained from ofﬁcial public 
sources (Kairos Magazine, May 2009). Administration costs were obtained from 
medical society physicians fee list (CBHPM, 2008, v.5). Since the time horizon of this 
analysis is one-year no discount rate was utilized. Costs are presented in Brazilian 
Reais (US$1.00^R$2.00 in May 2009). RESULTS: Total cost per patient was 
R$1534.36 for ibandronate and R$1951.26 for zolendronate. Administration costs 
represented about 11% of total cost of ibandronate (administrated four times a year) 
and 2% for zolendronate (administrated once a year). CONCLUSIONS: Findings 
suggest that IV ibandronate is a cost-saving therapy with potential to yield 21% 
reduction in total cost per patient under Brazilian private payer.
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COST-MINIMIZATION ANALYSIS OF BISPHOSPHONATES FOR RISK 
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BACKGROUND: Osteoporosis is a common illness frequently leading to serious 
adverse outcomes for patients. Hip, wrist and vertebral fractures have a considerable 
impact on both costs to health care system and lives of those who suffer from those 
events. Each year in the US, an estimated 1.5 million fractures occur due to osteopo-
rosis [Riggs and Melton, 1995]. Estimated incremental cost of osteoporosis related 
events in the subsequent years after fracture is US$4007 [Rousculp, 2007]. Bisphos-
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phonates are widely used and are considered an effective intervention for risk reduc-
tion of postmenopausal fractures. The 100% out-of-pocket purchase of medicines by 
patients is a reality in Brazil. So, a study under patient perspective is an important 
tool to help decision-making. OBJECTIVES: The present study was conducted to 
compare the cost of bisphosphonates used for risk reduction of post-menopause ver-
tebral and non-vertebral fractures under patient perspective in Brazil. METHODS: 
The most important bisphosphonates in the Brazilian market to patients are ibandro-
nate (oral and IV), zolendronate, alendronate and risendronate. There are no head-
to-head clinical trials comparing all the compounds. Studies of ibandronate [Eisman, 
2008] and zolendronate [McClung, 2007] demonstrated their non-inferiority against 
oral bisphosphonates. Therefore, a cost-minimization approach was taken. Drug 
consumer prices were obtained from ofﬁcial public sources [Kairos magazine, May 
2009]. Since the time horizon of this analysis is one-year, no discount rate was utilized. 
Costs are presented in Brazilian Reais (US$1.00^R$2.00 in May 2009). RESULTS: 
Total cost per patient was R$1534.36 for IV ibandronate, R$1685.83 for alendronate, 
R$1941.17 for oral ibandronate, R$1951,26 for zolendronate and R$2354.52 for 
risendronate. CONCLUSIONS: Findings suggest that IV ibandronate is a cost-saving 
therapy with potential of reducing the total treatment cost per patient from 9% up 
to 35%, when compared to alendronate and risendronate respectively, considering 
patient perspective in Brazil.
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ECONOMIC EVALUATION OF TRAMADOL/PARACETAMOL 
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OBJECTIVES: To compare the costs of treating osteoarthritis (OA) pain using com-
bination tramadol/paracetamol tablets, Non-Steroidal Anti-Inﬂammatory Agents 
(NSAIDs) alone or NSAIDs plus proton pump inhibitors (PPIs) from the perspective 
of the Spanish National Health System. METHODS: A decision-analytical model was 
constructed to analyse the cost outcomes of the three treatment strategies over 6 
months. A cost-minimisation approach was used, which considered data related to 
resource utilisation, medication costs and costs for the treatment of adverse events. 
Data, derived mainly from the clinical literature, were supplemented by inputs from 
a Delphi panel as well as ofﬁcial price and tariff lists. The base-case analysis considered 
direct medical costs, including those for treating gastrointestinal (GI) and cardiovas-
cular (CV) adverse events. Separate scenario analyses explored costs of NSAID-based 
regimens when renal events attributable to NSAIDs were considered. Univariate sen-
sitivity analysis and scenario analysis considering different levels of adverse events, 
risk and adverse events costs where also carried out. RESULTS: In the base-case 
analysis, costs for 6 months´treatment of OA pain using tramadol/paracetamol were 
a232.86 compared with a274.60 for NSAIDs  PPIs and a133.75 for NSAIDs alone. 
This provided a cost saving of a41.74 per patient over 6 months for tramadol/
paracetamol compared with NSAIDs  PPIs and a cost increase of a99.11 compared 
with NSAIDs alone. When renal adverse events of NSAIDs were considered, trama-
dol/paracetamol was cost saving compared with all NSAID-based regimens (saving 
a140.02 vs NSAIDs alone, a280.86 vs. NSAIDs  PPIs). Sensitivity analysis conﬁrmed 
these results using extreme values of probabilities and unit costs for all options. 
CONCLUSIONS: Tramadol/paracetamol is cost saving compared with NSAIDs  PPIs 
for the treatment of OA pain over a period of 6six months. Tramadol/paracetamol is 
also cost saving compared with treatment with NSAIDs alone if considering renal 
adverse events.
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OBJECTIVES: To evaluate the cost-effectiveness of a treatment sequence including 
tocilizumab 8mg/kg vs the standard treatment sequence (STS) currently used in moder-
ate/severe RA patients following inadequate response to previous DMARD therapy in 
Italy. METHODS: A cost-utility analysis was conducted from a payor’s perspective. 
An individual simulation model was employed to project lifetime cost, and QALYs 
for 10,000 patients. The model compared the STS (etanercept, adalimumab, ritux-
imab, abatacept, and palliative care) with a sequence in which tocilizumab replaces 
etanercept. Patient characteristics (age, HAQ-DI score, sex and weight) were based on 
data from three phase III clinical trials. A mixed treatment comparison was used to 
estimate ACR response rates for each of the treatments in both sequences. Patient data 
from the clinical trials were used to model the relationship between HAQ-DI scores 
and EuroQol (EQ-5D) utilities. Resource utilization, and treatment costs (acquisition, 
administration, and monitoring) were obtained from the literature and the Italian 
formulary. Clinical trial data and available literature provided a basis for ﬁtting 
appropriate distributions to the model parameters in order to perform probabilistic 
sensitivity analysis (PSA). Costs and QALYs were discounted at 3.5%. RESULTS: The 
model estimated that the treatment sequence including tocilizumab produced 0.275 
QALYs more than the standard sequence at additional cost of a984, resulting in an 
ICER of a3586 per QALY. Several sensitivity and scenario analyses showed that the 
model is robust to alternative parameter selections. The results of PSA (1000 samples) 
demonstrated that the ICER for the tocilizumab sequence is always below a threshold 
of a50,000. CONCLUSIONS: In patients who have failed DMARD therapy, the 
model consistently predicts that starting treatment with tocilizumab is cost-effective 
compared to the standard treatment sequence in Italy. The analysis suggests that 
switching between biologic treatments with different modes of action can be a cost-
effective option vs. TNF cycling.
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OBJECTIVES: The purpose of this study was to estimate the cost-utility of a topical 
formulation of diclofenac compared to a standard diclofenac oral preparation in 
patients treated for osteoarthritis of the knee having risk factors for gastrointestinal 
complications (older age or previous GI events). METHODS: For this cost-utility 
analysis, a Markov model was developed based on the model by Maetzel et al.. The 
analysis was performed according to a Minister of Health perspective over a ﬁve-year 
horizon. The model takes into account incidence of gastrointestinal events, incidence 
of complicated gastrointestinal events (perforation and bleeding, mortality), incidence 
of skin related adverse events and use of PPI. Utility estimates associated with each 
health states were taken from published sources. Cost of medications and costs associ-
ated with the management of gastrointestinal events (hospitalisation, emergency visits, 
physician’s visits, endoscopy, etc.) were considered. RESULTS: Cost-utility ratios are 
$39,342 per QALY for patients 65 to 74 years old, $22,019 for those 75 years old 
and more and $24,141 for patients with previous GI events. Base case results were 
robust to various deterministic and probabilistic sensitivity analyses. CONCLU-
SIONS: Topical diclofenac is a cost-effective alternative to oral diclofenac for patients 
having risk factors for GI complications.
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OBJECTIVES: Knee cartilage defects increase the risk of osteoarthritis and prosthesis. 
No standard treatment exists. ChondroCelect® is used in autologous chondrocytes 
implantation (ACI) to treat symptomatic knee cartilage defect. Its efﬁcacy and safety 
was demonstrated in a randomized controlled trial (TIG/ACT/01) vs. the surgical 
procedure microfracture. This study investigated the cost-utility of ChondroCelect® in 
Belgium. METHODS: A decision tree comparing ChondroCelect® to microfracture 
over a 40-year horizon was developed. Key variables were provided by the TIG/
ACT/01 trial (3-year clinical success using the Knee injury and Osteoarthritis Outcome 
Score [KOOS], 1-year structural repair/presence of hyaline [ good quality] cartilage 
based on International Cartilage Repair Society visual item [ICRS II] and utility scores 
by health state derived from the SF-36 questionnaire) and literature (incidence of 
osteoarthritis starting 15 years post-surgery [model assumption], incidence of total 
knee replacement [at 20 years] and prosthesis revision [at 35 years]). A patient chart 
review (n  82 patients) provided follow-up costs by surgery outcome. National tariffs 
were applied to medical resources used (Societal perspective). In accordance to Belgian 
guidelines annual discounting was applied to costs (3%) and effects (1.5%). RESULTS: 
The key TIG/ACT/01 outcomes with Chondrocelect® vs. microfracture were clinical 
success (KOOS) in 83% vs. 61% (p  0.018) and presence of hyaline cartilage (ICRS 
II) in 45% vs. 23% (p  0.010). The incremental cost/QALY gained was a29,397. 
The most sensitive parameters were the proportion of patients with hyaline cartilage 
and the correlation between hyaline cartilage formation and later avoidance of osteo-
arthritis. Probabilistic sensitivity analysis showed robustness of the results, with 60% 
of the simulations falling below a willingness-to-pay of a32,400/QALY (Belgian GDP/
capita, 2008). CONCLUSIONS: A high quality cartilage is expected to translate into 
reduced osteoarthritis development and thus fewer knee replacements. Corresponding 
mid/long term QALYs gained and cost savings made ChondroCelect® use in ACI 
cost-effective in Belgium.
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OBJECTIVES: Japan has been facing an aging society and the burden of illness for 
vertebral compression fracture (VCF) has become a signiﬁcant issue from an economic 
point of view as well as clinical point of view. Reduction of pain and improvement 
